A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
Status:
Recruiting
Trial end date:
2022-11-11
Target enrollment:
Participant gender:
Summary
In this study, four new tablet versions of two compounds will be investigated.
The aim of this study is to investigate the amount of the active ingredient and helping agent
in the blood after doses of four different tablet versions. The tablet versions, participants
will receive, i.e. the treatment arm participants will be assigned to, is decided by chance.
Participants will receive one treatment for 10 days in the first period. For the second
period, directly following, participants will receive a different treatment for five more
days.
The study can last for up to approximately 10 weeks for each participant. This includes a
screening period (up to 3 weeks), two treatment periods (together a total of 15 days) and a
follow-up visit (5 weeks after the last dosing)